Immunovant Ends Autoimmune Skin Disorder Program

Roivant Sciences Ltd. (NASDAQ:ROIV) announced that Immunovant Inc. (NASDAQ:IMVT) plans to halt the development of IMVT-1402 as a treatment for cutaneous lupus erythematosus (CLE). The decision follows recent proof-of-concept trial results that failed to reach...